Bioequivalence of two subcutaneous pharmaceutical products of interferon beta la.

@article{Girolamo2008BioequivalenceOT,
  title={Bioequivalence of two subcutaneous pharmaceutical products of interferon beta la.},
  author={Guillermo Di Girolamo and Marcelo Andres Kauffman and Eliseo B Gonz{\'a}lez and Mariana Papouchado and Alejandra Ram{\'i}rez and Guillermo Alberto Keller and C{\'e}sar Carbonetto and Susana Dabsys and Alejandro Vidal and A{\'i}da E Sterin-Prync and Roberto Alejandro Diez},
  journal={Arzneimittel-Forschung},
  year={2008},
  volume={58 4},
  pages={193-8}
}
Blastoferon, in the following referred to as the test product, is a pharmaceutical product of interferon beta la (CAS 220581-49-7) currently marketed as a biosimilar to the innovator Interferon beta la product (referred to as the reference product). Pharmacokinetics and pharmacodynamIcs assays are critically relevant to demonstrate similarity between biopharmaceuticals. The aims of the present study were to investigate the bioavailability (BA) of the test product (either absolute or relative to… CONTINUE READING